SPINT4

Model summary

A secreted Kunitz-type protease inhibitor that is stored in regulated secretory and acrosomal-like vesicles and released to the extracellular milieu, where it tightly and reversibly blocks trypsin-like serine proteases. By neutralizing targets such as trypsin and plasmin through a disulfide-stabilized inhibitory loop, it dampens fibrinolytic and coagulation activities and thereby contributes to hemostatic balance and extracellular protease control.

Predicted Gene Ontology terms

1. 01

   I begin with the InterPro architecture.

   The sequence is dominated by a single inhibitory module: IPR002223 (Pancreatic trypsin inhibitor Kunitz domain, residues 38–92) sits centrally and is encompassed by IPR036880 (Pancreatic trypsin inhibitor Kunitz domain superfamily, residues 29–97), indicating a canonical Kunitz fold—a disulfide-stabilized β-trefoil-like scaffold that presents a solvent-exposed reactive loop. The entire polypeptide is classified by IPR042943 (Kunitz-type protease inhibitor 4 family, residues 1–98), which specifies a lineage of secreted Kunitz inhibitors that target trypsin-like serine proteases. The ordered layout—an N-to-C single Kunitz module without additional catalytic or transmembrane features—dictates a non-enzymatic, tight-binding inhibitory role.

2. 02

   This Kunitz architecture causes serine-type endopeptidase inhibitor activity by inserting a P1 residue into the protease active-site cleft and forming an extensive disulfide-braced interface that blocks catalysis.

   That mechanism directly supports GO:0004867 serine-type endopeptidase inhibitor activity. The inhibitory chemistry readily explains suppression of trypsin and plasmin: both are trypsin-fold serine proteases whose active sites are neutralized by Kunitz loops. The same structural logic can extend to matriptase and kallikreins, which share the trypsin-like fold and are often controlled by Kunitz inhibitors.

3. 03

   From this molecular function, the biological role follows.

   Inhibiting plasmin and trypsin curtails fibrin degradation and dampens coagulation cascades, which causally yields negative regulation of blood coagulation (GO:0030195). By restraining protease activity in extracellular fluids and specialized secretory compartments, the inhibitor modulates hemostatic balance and matrix remodeling.

4. 04

   Cellular placement is inferred from secretion and storage pathways.

   The absence of intracellular catalytic domains and the presence of a secreted inhibitor scaffold point to extracellular deployment. The acrosomal vesicle annotation (GO:0001669 acrosomal vesicle) indicates trafficking through the regulated secretory pathway and storage in a specialized vesicle system; secretion from such compartments is consistent with deployment into extracellular spaces where protease control is needed. Thus, the protein is secreted and can be stockpiled in acrosomal-like vesicles before release.

5. 05

   Mechanistically, I hypothesize that the inhibitor is synthesized with a signal peptide, routed through the secretory pathway, and packaged into secretory/acrosomal vesicles.

   Upon release, its Kunitz domain binds and occludes the active sites of trypsin-like proteases, particularly plasmin and trypsin, and potentially matriptase and kallikreins. This positions it as a modulator of pericellular proteolysis and hemostasis. Likely interaction partners therefore include soluble and matrix-associated serine proteases and their cofactors in extracellular fluids and vesicle-rich secretory contexts.